The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double blind clinical trial

Table 2 Effects of Turmeric on Serum Levels of Liver Enzymes in Patients with NAFLD

Variables	Placebo, n = 32	Turmeric, n = 32	P1^a
FBS (mg/dL)
Before	100.70 ± 12.62	105.16 ± 12.85	0.167
After	97 ± 10.94	101.08 ± 10.51	0.134
P2^b	0.002	0.060
ALT (U/L)
Before	35.42 ± 18.51	39.56 ± 22.41	0.424
After	39.50 ± 21.15	30.51 ± 12.61	0.043
P2	0.307	0.038
AST (U/L)
Before	27.29 ± 11.53	26.81 ± 10.54	0.861
After	25.26 ± 9.66	21.19 ± 5.67	0.044
P2	0.303	0.021
GGT(U/L)
Before	32.91 ± 20.26	33.81 ± 17.50	0.767
After	31.59 ± 16.70	25.62 ± 9.88	0.046
P2	0.562	0.000
AST/ALT ratio
Before	0.829 ± 0.23	0.744 ± 0.23	0.146
After	0.763 ± 0.05	0.773 ± 0.21	0.887
P2	0.198	0.449

Values presented as mean ± SD
α analyzed by Pearson χ2, β analyzed by Fisher’s exact-test), NAFLD nonalcoholic fatty liver disease, FBS fasting blood sugar, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutamyl transpeptidase
^a,bP values indicate differences between the intervention and placebo groups at before and after intervention (Paired T Test)

ISSN: 1758-5996